The aim of this phase Ila trial is to provide evidence on safety, tolerability and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with early Parkinson's disease (PD). Fasudil has shown neuroprotective and pro-regenerative effects, modulated microglial activity and attenuated alpha-synuclein aggregation in PD models in vitro and in vivo. It has been licensed in Japan since 1995 for the treatment of vasospasms and has a beneficial safety profile arguing for its repurposing. Up to 15 trial centers in Germany will recruit patients. Blinded trial medication will be prepared and shipped by the University Pharmacy Leipzig. Fasudil in two dosages or placebo will be administered orally twice daily to 75 early PD patients for a total of 3 weeks. Safety, tolerability and symptomatic efficacy endpoints will be assessed up to 4 weeks after end of treatment. Its well-known safety profile and the lack of disease-modifying treatments for PD justifies its use in patients with early Parkinson's disease. ROCK-PD is a prerequisite for subsequent long-term clinical trials assessing disease-modification in PD in addition to symptomatic efficacy.

开始日期2023-09-11

申办/合作机构

Technische Universität München

JPRN-jRCTs031220704 / Recruiting临床2期IIT

Safety and Efficacy Exploratory Study of the Use of Fasudil hydrochloride for Vasospasm on arteriovenous fistula construction - SAEF-AVF study

开始日期2023-05-30

申办/合作机构-

100 项与盐酸法舒地尔相关的临床结果

登录后查看更多信息

100 项与盐酸法舒地尔相关的转化医学

登录后查看更多信息

100 项与盐酸法舒地尔相关的专利（医药）

登录后查看更多信息

302

项与盐酸法舒地尔相关的文献（医药）

2024-12-01·Reproductive Sciences

Transcriptomic Analysis and Finding of Potential Key mRNA Expression Profile in Human Cumulus Cells During in Vitro Culture and Different Passages Based on Integrated Bioinformatics Analysis

Article

作者: Qu, Guanglei ; Wang, Min

This study leveraged microarray datasets to investigate differentially expressed genes (DEGs) in cumulus cells and their relevance in predicting the successful implantation of embryos in human in-vitro fertilization procedures. The microarray data were obtained from the GEO database, encompassing samples of cumulus cells during in vitro culture and different passages. To ensure data consistency, inter-batch normalization was performed, and Principal Component Analysis (PCA) was applied to assess the impact of normalization on sample group clustering. The integrated dataset included samples from cumulus cells during in vitro culture, comprising 17,662 genes. Utilizing the "limma" software package, 1906 DEGs were identified, with 437 genes downregulated and 589 genes upregulated in the cumulus cells of infertility cases, while 748 genes were upregulated, and 1317 genes were downregulated in cumulus cells of successful implantation cases. Functional enrichment analysis utilized Gene Ontology, Metascape, and Kyoto Encyclopedia of Genes and Genomes pathway enrichment tools. Biological processes and molecular functions were enriched, including protein targeting, mRNA processing, and molecular binding among the identified DEGs. Furthermore, target prediction and functional enrichment analysis of microRNAs (miRNAs) revealed 25 key genes and 13 relevant miRNAs were identified. Notably, hsa-miR-149, hsa-miR23b, hsa-miR-877, hsa-miR593, hsa-miR-18a, hsa-miR25, hsa-miR185, mmu-miR-207, hsa-miR425, hsa-miR214, hsa-miR-129, hsa-miR-629, and hsa-miR-194 emerged as the most prominent miRNAs with potential regulatory roles in successful embryo implantation. This comprehensive analysis provides valuable insights into the molecular mechanisms underlying embryo implantation, offering potential targets for further research and therapeutic interventions in assisted reproductive technologies.

2024-09-01·No shinkei geka. Neurological surgery

[Postoperative Management of Aneurysmal Subarachnoid Hemorrhage].

Review

作者: Endo, Hidenori ; Sakata, Hiroyuki

Delayed cerebral ischemia(DCI) is one of the most significant complications of subarachnoid hemorrhage. Despite significant evolution in understanding DCI pathophysiology, vasospasm affecting cerebral vessels of large and moderate diameters remain the only clinically measurable component of DCI and is therefore the primary target for intervention in the postoperative management of subarachnoid hemorrhage. In Japan, fasudil hydrochloride and ozagrel sodium are widely used to prevent vasospasms; however, their effects are sometimes insufficient. Clazosentan, a selective endothelin receptor subtype A antagonist, reduces vasospasm-related morbidity and all-cause mortality following aneurysmal subarachnoid hemorrhage. This was demonstrated in a recent randomized phase 3 trial, leading to the approval of clazosentan by the Pharmaceuticals and Medical Devices Agency in Japan. Recent advances in our understanding of subarachnoid hemorrhage will facilitate improved management to reduce the incidence of DCI.

2024-09-01·AGING CELL

Sevoflurane‐induced overexpression of extrasynaptic α5‐GABA_AR via the RhoA/ROCK2 pathway impairs cognitive function in aged mice

Article

作者: Luo, Yuan ; Wang, Yongan ; Wang, Sixuan ; Wang, Shengran ; Wu, Jiangnan ; Wang, Zhun ; Zhang, Mengxue ; Yin, Yiqing ; Dong, Jinpeng

Abstract:

Perioperative neurocognitive disorder (PND) is a serious neurologic complication in aged patients and might be associated with sevoflurane exposure. However, the specific pathogenesis is still unclear. The distribution of α5‐GABAAR, a γ‐aminobutyric acid type A receptor (GABAAR) subtype, at extrasynaptic sites is influenced by the anchor protein radixin, whose phosphorylation is regulated via the RhoA/ROCK2 signaling pathway and plays a crucial role in cognition. However, whether sevoflurane affects the ability of radixin phosphorylation to alter extrasynaptic receptor expression is unknown. Aged mice were exposed to sevoflurane to induce cognitive impairment. Both total proteins and membrane proteins were extracted for analysis. Cognitive function was evaluated using the Morris water maze and fear conditioning test. Western blotting was used to determine the expression of ROCK2 and the phosphorylation of radixin. Furthermore, the colocalization of p‐radixin and α5‐GABAAR was observed. To inhibit ROCK2 activity, either an adeno‐associated virus (AAV) or fasudil hydrochloride was administered. Aged mice treated with sevoflurane exhibited significant cognitive impairment accompanied by increased membrane expression of α5‐GABAAR. Moreover, the colocalization of α5‐GABAAR and p‐radixin increased after treatment with sevoflurane, and this change was accompanied by an increase in ROCK2 expression and radixin phosphorylation. Notably, inhibiting the RhoA/ROCK2 pathway significantly decreased the distribution of extrasynaptic α5‐GABAAR and improved cognitive function. Sevoflurane activates the RhoA/ROCK2 pathway and increases the phosphorylation of radixin. Excess α5‐GABAAR is anchored to extrasynaptic sites and impairs cognitive ability in aged mice. Fasudil hydrochloride administration improves cognitive function.

项与盐酸法舒地尔相关的新闻（医药）

2024-11-12

·PRNewswire

Woolsey Pharmaceuticals Completes Patient Recruitment for High-Dose Cohort of ALS Study

NEW YORK, Nov. 12, 2024 /PRNewswire/ -- Woolsey Pharmaceuticals today announced the successful completion of patient recruitment (n=31) in the high-dose (300 mg/day) cohort of the REAL study, which is assessing BRAVYL® (oral fasudil) for the treatment of Amyotrophic Lateral Sclerosis (ALS). This follows promising biomarker and clinical findings from the study's standard-dose cohort. At the 180 mg/day dose (n=31), the biomarker Neurofilament Light (NfL), a sensitive indicator of neuronal damage and rate of ALS progression, decreased by 15% from baseline to 6 months (p=0.0006); of note, increased levels of NfL are associated with more rapid decline in function. Additionally, there were directionally positive clinical improvements compared to a matched historical control — a 17% lower decline in ALSFRS-R, a 37% lower decline in slow vital capacity (SVC), and a 56% lower decline in muscle strength. Moreover, greater decreases in NfL were correlated with less deterioration on the ALSFRS-R (p=0.028). Given these encouraging biomarker and clinical findings at the 180 mg/day dose, along with an excellent safety profile, Woolsey Pharmaceuticals made the decision to re-open the REAL study to explore the effects of BRAVYL at an increased dose of 300 mg/day. "Experience with this higher dose in ALS patients will be invaluable as we progress to a larger study," said Sven Jacobson, CEO of Woolsey Pharmaceuticals. "Furthermore, recently published results from a university-led, three-arm, double-blind study of fasudil in ALS patients found a relationship between dose and improved motor neuron function, which is very encouraging for our ongoing research," Jacobson stated, referencing "Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis [ROCK-ALS]: a phase 2, randomised, double-blind, placebo-controlled trial, Jan C Koch et at, The Lancet Neurology, November 2024)." Study results from the 300 mg/day dosing cohort are expected to be released by mid-2025. About ALS ALS is a fatal neurodegenerative disease characterized by inevitable, and often rapid, decline in patients as the disorder advances. Mean survival time is only two to five years. Accordingly, the ability to impede worsening represents a meaningful advancement in efforts to enhance the prognosis and quality of life of individuals impacted by the devastating condition. About Woolsey Pharmaceuticals Woolsey Pharmaceuticals' mission is to help usher in a new era of neurodegenerative disease treatment, saving and improving the lives of patients in need. SOURCE Woolsey Pharmaceuticals, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床2期临床结果

2024-11-11

·CPHI制药在线

采购直通车 | 制药行业的采购狂欢，40000+原料药产品等你来选！

制药在线精心策划的“采购直通车原料药专场”活动，已于近日盛大开启！这不仅是一场行业盛会，更是一次不容错过的商机！采购直通车是制药在线整合线上线下资源，精心打造的系列活动，旨在为制药行业的买卖双方提供高效、直接的对接平台。活动聚焦制药原料、原料药设备、精细化工、制药包装设备、实验室设备等关键领域，汇聚国内外知名制药企业，展示丰富多样的产品，促进供需双方深度交流与合作。每一次采购直通车活动，都是一次洞察行业趋势、解锁新商机的绝佳机会！作为“采购直通车”系列活动的首站，原料药专场无疑是最受瞩目的焦点，超过1300家国内外制药企业积极参与，产品展示超过40,000个，覆盖了所有关键领域，只为满足您的多元化需求！还在等什么，赶紧参与吧！扫码了解更多本场热门产品推荐维生素B1盐酸硫铵维生素C 1%生物素氟苯尼考氯霉素甲砜霉素四环素胶囊盐酸米诺环素替加环素青霉素V钾哌拉西林钠阿莫西林依泽麦布普司乐盐酸氨溴索盐酸特比萘芬头孢丙烯头孢噻呋钠扫码发现更多热门产品部分优选企业推荐（排序不分先后）天津中瑞药业股份有限公司天津中瑞药业股份有限公司是一家专业生产化学原料药、药用辅料、食品添加剂的高新技术企业，主要产品包括肌醇烟酸酯、盐酸特拉唑嗪、盐酸法舒地尔、盐酸特拉唑嗪、盐酸多巴胺、硫酸氢氯吡格雷、烟酸、烟酰胺。江西晨阳药业有限公司江西晨阳药业有限公司主要研发、生产销售医药中间体、原料药和其他化学品，目前主要生产产品为加替环合酯(喹啉羧酸乙酯）、加替羧酸（喹啉羧酸）、加替沙星、甲磺酸加替沙星、左氧氟环合酯、左氧氟羧酸、左氧氟沙星、盐酸左氧氟沙星、吡喹酮及其中间体、沙拉沙星、盐酸沙拉沙星及其中间体、盐酸莫西沙星及其中间体等。山东四环药业股份有限公司山东四环药业股份有限公司于2004年成立，是一家从事医药原料研发、生产与销售一体的科技型公司。公司主营产品有苯甲酸阿格列汀及中间体、曲格列汀琥珀酸盐、利格列汀及其中间体、泰诺福韦艾拉酚胺富马酸盐、LCZ696、新利司他、迈瑞替尼甲磺酸盐(AZD-9291)、依鲁替尼、巴瑞克替尼及其中间体、维利帕尼、盐酸头孢甲肟、苄星头孢匹林、4-羟基吡啶、头孢西酮酸及其中间体、头孢特仑酸、α-磺基苯乙酸、萘夫西林及中间体、磺苄西林钠、2-羟基-1-萘甲醛等。西安秦凯生物科技有限公司西安秦凯生物科技有限公司成立于2005年，是一家从事原料药和医药中间体研发、生产、销售的企业。公司现有产品6大类、100余种，主要产品为维生素D衍生物及其中间体、相关杂质。涉及到的维生素D衍生物有：艾地骨化醇、钙泊三醇、骨化三醇、帕立骨化醇、马沙骨化醇、骨化二醇、度骨化醇、阿尔法骨化醇。浙江海正药业股份有限公司海正药业是一家集研产销全价值链、原料药与制剂一体化、多地域发展的综合性制药企业，是全国最大的抗生素、抗肿瘤药物生产基地之一，公司专注于创新药、生物药、仿制药和高端原料药的研发、生产、销售，药品涵盖抗肿瘤、抗感染、心血管、内分泌、免疫抑制、抗抑郁、骨科等十多个治疗领域。石家庄新发化工科技有限公司 NEWPHARM是一家位于中国的活性药物成分（API）供应商，拥有超过25年的行业经验。公司不仅专注于API供应，还提供API材料的合同制造服务，并在拉丁美洲和亚洲市场实现了API产品的商业化。杭州德立化工有限公司杭州德立化工有限公司成立于2005年，专业生产医药原料药、医药中间体和其他化工品的工厂，主要产品包括屈螺酮、去氢孕酮、去氧孕烯、异维A酸、维A酸、阿维A酸、盐酸氨溴索、盐酸溴己新、地奥司明、氨甲环酸、对氯、对胺、酒石酸溴莫尼定等多种原料药和中间体。浙江天台药业股份有限公司浙江天台药业股份有限公司，成立于1998年6月，专业从事盐酸克林霉素、克林霉素磷酸酯和两性霉素B等抗生素、抗真菌系列特色原料药研发、生产及销售和原料药CRO&CDMO业务，是国内外盐酸克林霉素、克林霉素磷酸酯的主要生产商之一。更多优质企业等您来搜... 活动咨询申请入驻：万女士 T：02133392284 E：mili.wan@imsinoexpo.com 采购顾问：姚女士 T：02133392254 E：freya.yao@imsinoexpo.com 扫码查看更多厂家及产品信息您需要的这里都有哦！ END

带量采购

2024-07-08

·PRNewswire

Woolsey Pharmaceuticals Announces Treatment Of First Patient with Higher-Dose BRAVYL in The REAL Amyotrophic Lateral Sclerosis (ALS) Study (NCT05218668)

NEW YORK, July 8, 2024 /PRNewswire/ -- Woolsey Pharmaceuticals, a clinical-stage drug development company, announced that the first patient has started treatment at 300 mg/day in the REAL study, which is evaluating the effects of BRAVYL in Amyotrophic Lateral Sclerosis (ALS). As recently announced, participants treated with 180 mg/day BRAVYL in the REAL study experienced a 15.5% decrease (improvement) in NfL from baseline to 6 months (p<0.001). Since NfL in the ALS population tends to increase by a mean of 11% in 6 months, this suggests that 180 mg/day BRAVYL could potentially reduce NfL up to 26% versus a control group. Moreover, greater decreases in NfL were correlated with less deterioration on the ALSFRS-R (Spearman's coefficient = -0.45, p=0.028) implying that early clinical benefits of reducing NfL may be seen contemporaneously with the NfL reductions by BRAVYL. A "propensity matched" analysis was performed wherein 12-month clinical outcomes from REAL were compared with those from a matched cohort selected by identifying 31 patients from the Ceftriaxone ALS Study database that were most similar (based on pre-treatment age, ALSFRS-R, time from onset of ALS, and other important parameters) to each REAL patient. The rate of deterioration in ALSFRS-R was improved in REAL vs. the matched controls by 28% (p=0.12). REAL patients also had a 42% (p=0.05) slower deterioration in SVC (breathing) and a 50% (p=0.06) slower rate of muscle strength decline, driven mostly by lower limb muscles with a 71% (p=0.04) reduction in weakening and a more modest 37% (p=0.22) reduction in weakening of upper limb muscles. An analysis that matched REAL patients recruited in Australia to the Australian MND Registry (a longitudinal registry, not a study) yielded directionally similar ALSFRS-R and SVC findings while muscle strength could not be analyzed as the registry does not contain such data. "The dosing of the first participant at 300 mg is another important program milestone," notes Sven Jacobson, CEO of Woolsey. "This next phase will allow us to evaluate the safety and tolerability of a higher dose, in preparation for our planned phase 2b study. Our goal is to continue to advance development of BRAVYL for people living with ALS, in hopes that we can slow the progression of the disease and improve their quality of life." ABOUT ALS ALS is a fatal neurodegenerative disease characterized by inevitable, and often rapid, decline in patients as the disorder advances (mean survival time is only two to five years). Accordingly, the ability to impede any worsening represents a meaningful advancement in efforts to enhance the prognosis and quality of life of individuals impacted by this devastating condition. ABOUT WOOLSEY PHARMACEUTICALS Woolsey Pharmaceuticals is expanding the boundaries of medical science. Our lead indication is Amyotrophic Lateral Sclerosis (ALS), a progressive and debilitating disease that ultimately is fatal. Our mission is to help usher in a new era of neurodegenerative disease treatment, saving and improving the lives of patients in need. SOURCE Woolsey Pharmaceuticals, Inc.

临床结果临床2期

100 项与盐酸法舒地尔相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03115	盐酸法舒地尔	C04AX32	DB08162

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
脑缺血	日本	Asahi Kasei Corp.	1995-06-30
颅内血管痉挛	日本	Asahi Kasei Corp.	1995-06-30

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肌萎缩侧索硬化	临床2期	美国	Woolsey Pharmaceuticals, Inc.初创企业	2021-12-22
肌萎缩侧索硬化	临床2期	澳大利亚	Woolsey Pharmaceuticals, Inc.初创企业	2021-12-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


REAL (PRNewswire) 人工标引	临床2期	肌萎缩侧索硬化 Neurofilament Light Chain	31	BRAVYL	遞餘憲願鹹廠窪鏇蓋願(鬱襯遞願廠構廠襯選糧) = 窪淵膚遞範鑰製選網簾壓獵醖夢鏇鏇製齋繭鹽 (窪網窪糧憲願繭夢衊範 ) 更多	积极	2024-06-19
NCT03404843 (CTgov)	临床2期	心血管疾病	31	placebo (Young Saline)	糧構糧製齋窪憲蓋膚簾(艱蓋簾選鹽獵願膚獵蓋) = 製廠觸壓觸廠網淵鑰鹹鹹鑰艱鹽壓醖範衊鬱醖 (鏇壓觸鑰襯壓觸積膚齋, 糧膚壓獵願鑰選餘繭壓 ~ 鬱築顧憲壓鑰齋膚築襯) 更多	-	2020-02-27
				fasudil hydrochloride (Young Fasudil)	糧構糧製齋窪憲蓋膚簾(艱蓋簾選鹽獵願膚獵蓋) = 鹹餘積觸鑰蓋選鑰壓夢鹹鑰艱鹽壓醖範衊鬱醖 (鏇壓觸鑰襯壓觸積膚齋, 蓋糧鹽遞鹽蓋繭憲製蓋 ~ 鏇簾憲醖膚醖蓋顧襯觸) 更多
ARVO2017	N/A	视网膜脱离	-	Fasudil	衊製夢簾獵壓醖憲選網(鑰鑰窪淵廠範窪夢糧網) = 51% reduction 積膚構選廠築廠淵鹹窪 (壓鏇鑰鏇衊蓋範齋選築 )	-	2017-05-07
NCT00670202 (CTgov)	临床2期	颈动脉狭窄	2	Fasudil Hydrochloride (Drug: Fasudil Hydrochloride)	願糧廠齋積選艱壓構蓋(鏇鬱壓鑰製簾繭遞憲襯) = 襯鹽範構醖製衊餘壓壓積醖窪鏇繭齋淵範構製 (網選繭願齋襯艱餘衊衊, 窪鏇製範積憲醖簾獵鹽 ~ 糧蓋鑰壓鹹範淵窪鑰鏇)	-	2017-03-29
				Placebo Oral Tablet (Drug: Placebo Oral Tablet)	願糧廠齋積選艱壓構蓋(鏇鬱壓鑰製簾繭遞憲襯) = 觸艱鹹齋積醖積構衊憲積醖窪鏇繭齋淵範構製 (網選繭願齋襯艱餘衊衊, 憲鹹襯窪壓範鑰醖膚築 ~ 簾糧憲繭獵願餘淵餘蓋)
PO512 (AAO2016)	N/A	糖尿病性黄斑水肿	-	IVB/IVF group	觸夢繭觸鑰蓋顧積願鏇(鹽鑰糧鏇積艱繭遞餘鹹) = BCVA changes were consistent with CMT changes 齋齋齋觸衊廠簾範積淵 (鬱積艱蓋鏇簾積艱襯膚 )	积极	2016-10-17
				IVB group
ERS2013	N/A	肺动脉高压	6	Fasudil	襯鏇憲繭鑰繭獵鬱壓築(築夢構顧鏇簾窪憲繭夢) = 範糧艱願鑰夢艱膚蓋範鏇網襯衊齋廠夢夢醖衊 (構窪糧鬱鬱蓋構繭齋憲, 18.0)	不佳	2013-09-01
				fasudil	襯鏇憲繭鑰繭獵鬱壓築(築夢構顧鏇簾窪憲繭夢) = 窪範繭繭餘遞鬱築鹽鑰鏇網襯衊齋廠夢夢醖衊 (構窪糧鬱鬱蓋構繭齋憲, 4.5)
ARVO2009	N/A	脉络膜新生血管	-	Fasudil 20mg/kg	廠遞顧構繭鏇蓋淵衊鬱(製範襯夢願遞鑰繭鏇觸) = 襯鹹醖網襯遞膚築糧遞遞構繭膚夢鹽遞獵願艱 (獵齋糧觸網艱範顧醖襯 ) 更多	积极	2009-04-01
				Vehicle	廠遞顧構繭鏇蓋淵衊鬱(製範襯夢願遞鑰繭鏇觸) = 衊鹹鹹壓願積膚鹽醖簾遞構繭膚夢鹽遞獵願艱 (獵齋糧觸網艱範顧醖襯 ) 更多